Amaran Biotechnology Inc., a subsidiary of Taiwan’s OBI Pharma Inc., today announced that the construction of its fully-automated aseptic filling line and facilities, a first in Taiwan, has been completed. The new facility minimizes the risks of human factors affecting the quality of the pharmaceutical products, and substantially enhances their safety. The project is now entering the final process validation phase of the medium fill procedures.
The Board of Directors of Amaran Biotechnology, Inc. passed a resolution on September 28th to exchange 67 percent of the Company’s shares with OBI Pharma, Inc. The share exchange transaction will be 53,466,000 shares of Amaran Biotech’s common stock in exchange for 10,693,200 shares of OBI Pharma’s common stock. OBI Pharma intends to issue new shares and increase capital in this transaction.
Tessie Che, chairperson & GM of Amaran Biotech shares the story of how she came to lead the company and set its course to become a leading specialty biopharma CMO that leverages high-quality products and best manufacturing practices above all else. As a veteran in the life sciences and pharma industries, Che also shares her insights on the major trends shaping biopharma in Taiwan and internationally. Finally, Che concludes with a message about Amaran’s ambitions to set the gold standard for Taiwanese drug production.
BioAsia-Taiwan 2019 will take place in the Taipei Nangang Exhibition Center and CTBC Financial Park on July 24 to July 28. BioTaiwan has established itself as one of the largest annual biotech events in Asia for the past 16 years. The Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan Bio) have come together to present BioAsia-Taiwan. This year’s event themed “Biotech as the Next Growth Engine for Asia" will attract more than 1,500 attendees from 25 countries.
INTERPHEX JAPAN 2019, Japan’s largest and Asia’s leading exhibition for pharmaceutical manufacturing and packaging technologies, will take place in Tokyo Big Sight on July 3 to July 5. INTERPHEX Week Japan consists of 4 exhibitions for pharmaceutical technologies, INTERPHEX JAPAN, in-Pharma Japan, BioPharma Expo and PharmaLab Japan. There will be over 1,280 exhibitors and visitors from all over Asia at this event.
BioTaiwan 2018 will take place in the Taipei Nangang Exhibition Center and CTBC Financial Park on July 18 to July 22. BioTaiwan 2018 is made up of 5 events, including the BioBusiness Asia Conference, Greater China & Asia-Pacific Opportunities Conference, Company Presentations, BioTaiwan Exhibition and One-on-one Partnering. This international conference has become a key event for Taiwan’s biotechnology industry.
Amaran Biotechnology, Inc. has been awarded cGMP certification from the Taiwan Food and Drug Administration (TFDA). The certificate demonstrates that Amaran Biotechnology manufactures and maintains a level of compliance in accordance with the Pharmaceutical Inspection Convention/Co-Operation Scheme (PIC/s) Guide to Good Manufacturing Practice (GMP). Its scope covers the manufacture of active pharmaceutical ingredients (API) at Amaran’s manufacturing facility, which is located in Hsinchu Biomedical Science Park.
Amaran Biotechnology, Inc., a biopharmaceuticals manufacturer and leading manufacturer of a key protein utilized in immunotherapy development pipelines Stellar Biotechnologies, Inc. (Nasdaq: SBOT), have entered into an exclusive multi-year supply agreement in connection with clinical development studies of immunotherapies for metastatic breast cancer and other cancers.